ProFactor Pharma

Transforming treatment of haemophilia

ProFactor Pharma Ltd (PFP) is developing factor VIII (FVIII) for the treatment of Haemophilia A. 

Our business is to manufacture low cost recombinant FVIII to a severely undersupplied world market.

According to the World Health Organisation (WHO) and the World Federation of Hemophilia around two thirds of the haemophilia patient population receive inadequate or no treatment at all.

Recent News